- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07804277
Comparative Study of the Tomey FT-1000, and Goldmann Applanation Tonometer (GAT)
This study is intended to evaluate the agreement between Intraocular pressure(IOP) measurements obtained with the FT-1000 non-contact tonometer and a GAT to confirm the feasibility of the measurement procedures.
This is a prospective comparative study that will be conducted at one clinical site in the United States. Subjects who sign an informed consent form and fulfill all inclusion and exclusion criteria will undergo FT-1000 measurements followed by Goldmann applanation tonometry during a single study visit.
The primary analysis will be performed using one preselected study eye from each subject. Measurements from the fellow eye, when available, may be summarized as exploratory analyses but will not contribute to the primary effectiveness analysis.
In general, descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be used to summarize continuous variables. Frequencies and percentages will be used to summarize categorical variables. The number of accepted scans and the total number of scans evaluated will be summarized by scan type, device, and subject population.
Agreement between the FT-1000 and the Goldmann applanation tonometer will be evaluated using the study eye measurements by calculating the mean difference, standard deviation (SD), 95% limits of agreement (LOA), Bland-Altman plots, Deming regression, and Pearson correlation coefficient.
Exploratory analyses may also be performed using fellow-eye measurements.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed.
- Subjects who are able to understand and follow the study procedures and instructions provided by the clinical staff.
- Subjects who voluntarily provide written informed consent.
- Subjects who satisfy all study eligibility requirements and are able to undergo both FT-1000 and Goldmann applanation tonometry measurements during the study visit.
Exclusion Criteria:
- Subjects with only one functional eye.
- Subjects with poor or eccentric fixation in either eye.
- Subjects with a history of corneal surgery, including corneal laser or refractive surgery (e.g., LASIK).
- Subjects with corneal scarring, keratoconus, or any other clinically significant corneal pathology.
- Subjects with an active corneal or conjunctival infection or inflammation in either eye.
- Subjects with microphthalmos or buphthalmos.
- Subjects who are unable or unwilling to remove contact lenses before study measurements.
- Subjects with clinically significant dry eye disease that, in the investigator's opinion, may affect tonometry measurements.
- Subjects with blepharospasm (lid squeezing) or nystagmus that may interfere with accurate measurements.
- Subjects with abnormal central corneal thickness (CCT).
- Subjects with any condition or circumstance that, in the opinion of the investigator, could place the subject at significant risk, interfere with study participation, or confound interpretation of the study results.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Low Intraocular pressure(IOP) Group: 7-16 mmHg
Group with IOP of 7-16 mmHg; 10 subjects.
|
Intraocular pressure measurement by non-contact tonometer and applanation tonometer.
|
|
Middle Intraocular pressure(IOP) Group: >16 to <23 mmHg
Group with IOP of >16 to <23 mmHg; 10 subjects.
|
Intraocular pressure measurement by non-contact tonometer and applanation tonometer.
|
|
High Intraocular pressure(IOP)Group: ≥23 mmHg
Group with IOP of ≥23 mmHg; 10 subjects.
|
Intraocular pressure measurement by non-contact tonometer and applanation tonometer.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety of the test devices
Zeitfenster: Through study completion, approximately 3 days
|
Any adverse events observed or reported during the study visit will be assessed and documented.
|
Through study completion, approximately 3 days
|
|
Agreement of the Intraocular pressure (IOP) mmHg between the test devices and predicate device
Zeitfenster: Through study completion, approximately 3 days
|
Agreement of the Intraocular pressure (IOP) mmHg between the FT-1000 and the Goldmann Applanation Tonometer(GAT) will be evaluated using the study eye measurements by calculating the mean difference, standard deviation (SD), 95% limits of agreement (LOA), Bland-Altman plots, Deming regression, and Pearson correlation coefficient. Exploratory analyses may also be performed using fellow-eye measurements. |
Through study completion, approximately 3 days
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TomeyFT-1000-001
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .